Objective: Exclusion of patients with a history of other cancer treatment except in situ situation has been considered to be inevitable for clinical trials investigating survival outcome. However, there have been few reports confirming these influences on surgical outcome of lung cancer patients ever. Methods: Multi-institutional, individual data from patients with non-small cell lung cancer resected between 2000 and 2013 were collected. The patients were divided into two groups: those with a history of gastrointestinal tract cancer (GI group) and those without any history (non-GI group). We compared the outcomes with well-matched groups using propensity scoring to minimize bias related to the nonrandomness. The influence of gastrointestinal tract cancer stage, disease-free interval, and treatment method for gastrointestinal tract cancer on the surgical outcome of non-small cell lung cancer was examined. Results: We analyzed 196 patients in the GI group and 3732 in the non-GI group. In unmatched cohort, multivariate analyses showed that a history of gastrointestinal tract cancer did not affect overall survival or recurrence-free survival. Independent predictors of poor prognosis included older age, male sex, high carcinoembryonic antigen levels and advanced clinical stage of nonsmall cell lung cancer. The two groups in the matched cohort demonstrated equivalent overall survival and recurrence-free survival, even in patients with clinical stage I. Gastrointestinal tract cancer stage, disease-free interval and treatment method for gastrointestinal tract cancer were not associated with outcomes. Conclusions: History of early gastrointestinal tract cancer completely resected is not always necessary for exclusion criteria in clinical trial of lung cancer.
Introduction
Recently, the inclusion and exclusion criteria of clinical trials have become increasingly complex and strict to enhance study quality (1) . The eligibility criteria of most clinical trials are a serious obstacle to patient accrual (2) . Patients with a history of cancer during the 5 years before a clinical trial have been unconditionally excluded from such trials, even though the impact of history of other cancer on the cancer patient prognosis has been barely validated. Gerber et al. points out that there are no data about the assumption that a prior cancer could interfere with study conduct or outcomes (3) . Meanwhile, survival rate of lung cancer patients has been improving in many developed countries because of early detection, better diagnostic technology, progressive multimodal therapy and evolving molecular target therapy (4) (5) (6) (7) . However, these improvements in prognosis have caused the new issues of the increased prevalence of multiorgan cancer and metachronous multiple primary cancer and resulted in a significant barrier to enrollment in clinical trials (8) . If the impact of cancer history during the previous 5 years proves to be reasonably small, these patients could be included in clinical trials. This study aims to determine the feasibility of including patients with a history of gastrointestinal (GI) tract cancer during the last 5 years in clinical trials for lung cancer by analyzing the clinical features and prognosis of patients with lung cancer and a history of treatment for gastric and/or colorectal cancer, a cohort that is currently excluded from most clinical trials.
Patients and methods
We retrospectively collected individual data from three institutions (Juntendo University, Hiroshima University and National Cancer Center Hospital East) from patients who underwent complete pulmonary resection of primary non-small cell lung cancer (NSCLC) between January 2000 and June 2013. The patients were divided into two groups: those who had undergone complete resection of lung cancer as well as previous treatment for GI tract cancer (GI group) and those who had undergone complete resection of lung cancer and did not have a history of any other cancer (non-GI group). However, the patient prognosis or cancer malignancy differs from the type of cancer. In this study, we analyzed lung cancer patients receiving GI cancer treatment because GI cancer is relatively manageable and shows a uniform biological behavior. In the GI group, only those patients who had undergone curative resection for GI tract cancer were included. The indications for primary lung cancer resection were discussed by each institutional cancer board on the premise that all past cancers were controlled. The patients were aged 20-79 years; this age range has been adopted as an eligibility criterion for most surgical clinical trials. Patients with cancers in organs other than GI tract were excluded from this study. We collected linkable, anonymous individual data for patients with surgically resected lung cancer. Data collection and analysis methods were approved by the Institutional Review Board of the National Cancer Center Hospital East (approval number: 2013-106) in August 2013 and were also approved by the Institutional Review Boards at the other two institutions.
We reviewed the following clinicopathological information: age, sex, preoperative serum carcinoembryonic antigen (CEA) levels, clinical stage of lung cancer, pathological stage of GI tract cancer, disease-free interval (DFI), surgical method, lymph node dissection and histological type of lung cancer. DFI was defined as the period between the date of GI tract cancer treatment in which the patients became actually free from GI tract cancer and the date of lung cancer surgery. We paid special attention to preoperatively available factors that enabled us to choose a therapeutic strategy for lung cancer. These clinicopathological characteristics were compared between the GI and non-GI groups.
The primary interest of this study was to assess whether the presence of GI tract cancer affected the following time-to-event end points: (i) overall survival (OS), defined as the duration between the date of lung cancer surgery and the date of death from any cause or the date of the last follow-up in living patients and (ii) recurrencefree survival (RFS), defined as the duration between the date of lung cancer surgery and the date of death from any cause or the date of lung cancer relapse, whichever occurred first. To minimize bias related to the nonrandom nature of GI tract cancer, we performed several Cox analyses using propensity scores and compared the results with those of simple and conventional analyses. The estimated propensity score (EPS) was the one-dimensional balancing score as well as an individual patient's predicted probability of the presence of GI tract cancer, given the available baseline covariates of preoperatively determined factors (Table 1) , The EPS was determined using a logistic regression model in which the response variable was the indicator of GI tract/lung cancer. Age and CEA levels were included in the model as continuous variables. The results of analyses using the EPS were compared with those of univariate Cox analysis adjusted for the GI tract indicator only (Model 1) and multivariable Cox analysis that included the covariates shown in Table 3 to the linear term of Model 1 (Model 2).
To perform analyses using the EPS, we completed the following steps. First, patients with GI tract cancers were matched, without replacement, with those with lung cancer only in the proportion of 1:2. A greedy matching method was implemented using a standardized deviation width of 0.2 for the logit transformation of the EPS following Austin's simulation (9) . After matching, the GI tract indicator was adjusted using the univariate Cox model (Model 3). Finally, we employed the inverse probability weighting (IPW) marginal structural Cox regression analyses using three types of weights: (i) the standard weight, which used the reciprocal of the EPS (Model 4); (ii) the stabilized weight, where the numerator of the standard weight was replaced with the marginal prevalence probability of the presence of GI tract cancer (Model 5); and (iii) the exposed weight, determined using the weight that replaced the numerator of the standard weight with the EPS (Model 6).
Demographic characteristics were compared using the chi-square test for categorical variables. All results for Models 1-6 were compared using estimated hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs). Empirical (i.e. robust or sandwich) standard error was used to construct 95% CIs for Models 3-6. The Kaplan-Meier method and log-rank test were used to evaluate differences in survival curves and estimate the OS or RFS rates at a specific time point. We evaluated the imbalance in patient characteristics before and after caliper matching using the standardized difference (10). We then determined whether the standardized difference was less than 0.10, which was said to denote a negligible imbalance (11) . In addition, subgroup analyses based on the matched data set were conducted in relation to clinical stage I lung cancer, pathological stage I and II GI tract cancer, DFI and surgical resection only for GI tract cancer. Most clinical studies related to cancer surgery exclude the cancer patients with other cancer within 3 or 5 years. So in this study, we compared non-GI group and two GI groups divided by DFI 3 or 5 years. All statistical analyses were performed using SAS Release 9.3 (SAS Institute, Inc, Cary, NC).
Results
The date of data cut-off is April 2013 at Juntendo University, August 2013 at Hiroshima University and October 2013 at National Cancer Center Hospital East. Median follow-up time of these data is 37 months. Of the 3928 patients, 196 (5.0%) lung cancer patients had a history of GI tract cancer treatment, while 3732 (95.0%) had no history of other cancers (Fig. 1) . The clinical and pathological characteristics are summarized in Table 1 . Patients in the GI group were significantly older (66 years and older) and predominantly male. The lung cancers in the GI group were at an earlier clinical stage, and more patients underwent limited resection.
Numbers of events for OS and RFS were 37 and 51 in GI group and 787 and 1130 in non-GI group, respectively. Among the 196 patients in the GI group, 34 developed lung cancer recurrence, 1 showed recurrence of colorectal cancer and 2 showed recurrence Non-GI group n = 3732 GI group n = 196 GI group (n = 196) . stomach cancer only (n = 85) . colorectal cancer only (n = 103) . both cancers (n = 8)
Collected data set (n = 4795)
• primary non-small cell lung cancer of stomach cancer. The patient who died from recurrence of colorectal cancer demonstrated pathological stage I. The two patients who died from recurrence of stomach cancer demonstrated pathological stage III and IV. The OS and RFS in all patients with clinically staged lung cancer showed no statistically significant difference between the two groups before matching ( Fig. 2A and B) . Table 2 lists the independent prognostic factors for OS and RFS for all lung cancer patients using log-rank test and multivariable analyses in the Cox proportional hazard model. Younger age, female sex and low preoperative CEA levels were independent predictors of good prognosis. An early clinical stage of lung cancer had the strongest impact on OS (HR, 2.22; 95%CI, 1.91-2.59) and RFS
The GI group patients were matched with non-GI group patients in a 1:2 ratio (Table 3 ). The EPS histograms of the two groups revealed a similar distribution curve (data not shown). Matching using this score allowed us to find two well-matched groups, as shown in Table 3 . There were no significant differences in any clinical characteristics tested. All factors showed a standardized difference of <0.10, denoting a negligible imbalance between the two groups after matching.
There were no significant differences in OS or RFS between these matched subgroups of patients (Fig. 3A and B) Figure 2 . Kaplan-Meier curve for OS comparing the GI and non-GI groups before matching by EPS: (A) OS and (B) RFS. EPS, estimated propensity score; OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; 95% CI, 95% confidence interval.
group compared with that for the non-GI group was approximately 0.9 in various models, including IPW analysis (Supplementary Table) .
When only clinical stage I lung cancer patients were analyzed, the OS and RFS curves for the two matched groups were equivalent ( Fig. 4A and B). The prognosis of the group with pathological stage I or II GI tract cancer was equivalent to that of the non-GI group (Fig. 4C and  D) . The GI group was divided into two subgroups according to 5-year ( Fig. 4E and F ) and 3-year DFI ( Fig. 4G and H) , and the OS and RFS of these subgroups were compared with those of the non-GI group; no significant differences were observed. To explore the influence of surgical resection of GI tract cancer on lung cancer prognosis, we compared the outcomes of the non-GI and GI groups, excluding cases of endoscopic mucosal resection. No differences in prognosis were observed between the two groups ( Fig. 4I and J) .
Discussion
The survival of cancer patients has improved with advances in therapeutic developments. Hayat et al. analyzed the Surveillance, Epidemiology, and End Result (SEER) database and pointed out that this improvement in cancer survival has resulted in an increase in the prevalence of cancer (12) . The recent increase in cancer survivors and prolonged life expectancy will also contribute to the development of multiple primary or multiorgan cancers. Some researchers have reported that the number of cancer survivors is growing (12, 13) . According to the SEER database in the USA, second or higher order cancers account for~16% of incident cancers (12) . In the present study, lung cancer patients with a history of treatment of other organ cancers accounted for up to 13.5% of all patients with lung cancer resection after the year 2000 (data not shown). Therefore, we encounter patients with lung cancer and synchronous or metachronous multiorgan cancers or multiple primary lung cancers. However, patients with a history of cancer have been unconditionally excluded from most previous pivotal clinical trials. Recent report pointed out that the estimated proportion of patients excluded because of prior cancer is up to 18% in lung cancer clinical trial (3). The major reason for excluding patients with a history of cancer is that a previous cancer may have a significant impact on survival and the management strategy chosen for the current cancer. Some researchers have reported that lung cancer patients with a history of multiorgan cancer have a poor prognosis (13), while others have reported equivalent outcomes (14, 15) . In this study, univariate and multivariable analyses comparing the GI and non-GI groups revealed some differences in characteristics: the GI group patients were significantly older and more predominantly male with their lung cancers in earlier clinical stages. Therefore, we compared matched groups using EPS to minimize the influence of background bias on outcome. In the matched subgroup analyses, the GI and non-GI groups had equivalent prognoses, regardless of DFI, clinical stage of lung cancer, pathological stage of GI tract cancer or treatment method for GI tract cancer. In Japan, patients with pathological stage I or II gastric or colorectal cancer have very good prognoses; the reported 5-year survival rate for each disease is over 80% (16, 17) . In addition, the favorable outcome of the GI group may be due, in part, to the small population of patients with pathological stage III GI tract cancers in this study and the inclusion of many otherwise healthy patients. This observation may indicate that each institutional cancer board selected patients with a good prognosis. Advances in diagnostic modalities such as positron emission tomography and magnetic resonance imaging may also contribute to favorable outcomes by decreasing the risk of disseminated disease. Improvements in minimally invasive treatments such as endoscopic and laparoscopic surgery may also influence the prognosis of lung cancer. The presence or absence of a history of previous GI tract cancer treatment had little effect on lung cancer prognosis if the patients were appropriately selected according to their condition and imaging surveillance. Possible explanations for the occurrence of multiorgan cancer (besides chance incidence due to prolonged life expectancy) have been proposed. One well-known factor is the presence of genetic disorders such as the Li-Fraumeni syndrome, characterized by germline mutations in the TP53 tumor suppressor gene (18) , familial adenomatous polyposis (19, 20) and multiple endocrine neoplasia (21, 22) . Carcinogenic factors such as tobacco and alcohol consumption are known to play an important role in the development of multiple cancers including lung cancer, nasopharyngeal cancer, laryngeal cancer and bladder cancer (23, 24) . The increased use of radiotherapy and chemotherapy has been also thought to induce secondary cancers (25) . Hall and Wuu reported that intensitymodulated radiation therapy was likely to increase the incidence of secondary malignancies by almost 50% compared with conventional radiotherapy (26) . Hennig et al. reported a higher percentage of cervical cancers among female lung cancer patients in his study, and he speculated that human papillomavirus infection, a wellknown risk factor for cervical cancer, is also a possible carcinogenic factor for lung cancer (27, 28) . This type of study may help in clarifying the mechanisms underlying the development of cancer.
Multiorgan cancers have diverse causes, including environmental factors, hereditary factors, personal preference and therapeutic inducement. This broad range of causative factors creates difficulty in establishing a standard therapeutic strategy against cancer. In addition, substantial advances in cancer treatment will lead to a progressive increase in patients with multiple cancers in the future. 
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